Navidea Biopharmaceuticals, Inc. (NAVB)

NYSEAMERICAN: NAVB · IEX Real-Time Price · USD
0.340
+0.037 (12.18%)
Mar 21, 2023, 3:59 PM EDT - Market closed
12.18%
Market Cap 11.00M
Revenue (ttm) 115,390
Net Income (ttm) -17.38M
Shares Out 32.36M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,546
Open 0.330
Previous Close 0.303
Day's Range 0.318 - 0.340
52-Week Range 0.160 - 1.240
Beta 1.52
Analysts Buy
Price Target 5.10 (+1,400.44%)
Earnings Date Mar 21, 2023

About NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 1992
Employees 11
Stock Exchange NYSEAMERICAN
Ticker Symbol NAVB
Full Company Profile

Financial Performance

In 2021, NAVB's revenue was $531,513, a decrease of -41.91% compared to the previous year's $915,013. Losses were -$11.73 million, 3.03% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for NAVB stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 1,400.44% from the latest price.

Price Target
$5.1
(1,400.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

6 days ago - Business Wire

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company's Cancer Immunotherapy Pipeline

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immu...

2 months ago - Business Wire

Navidea Biopharmaceuticals Files Appeal in CRG Case

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immu...

3 months ago - Business Wire

Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company's Phase 3 Trial in Rheumatoid Arthritis

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immu...

4 months ago - Business Wire

CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

DUBLIN, Ohio--(BUSINESS WIRE)--The seventh bullet under Third Quarter 2022 Highlights and Subsequent Events should read: Received an additional $1.0 million under a bridge loan from the Company's Vi...

4 months ago - Business Wire

Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immu...

4 months ago - Business Wire

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

4 months ago - Business Wire

Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

4 months ago - Business Wire

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

5 months ago - Business Wire

Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

6 months ago - Business Wire

Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

6 months ago - Business Wire

Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

7 months ago - Business Wire

Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney's Fees

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

7 months ago - Business Wire

Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immuno...

7 months ago - Business Wire

Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immuno...

7 months ago - Business Wire

Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

7 months ago - Business Wire

Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

7 months ago - Business Wire

Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

8 months ago - Business Wire

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

8 months ago - Business Wire

Navidea Biopharmaceuticals Reminds Investors of Today's Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

8 months ago - Business Wire

Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

8 months ago - Business Wire

Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

8 months ago - Business Wire

Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

9 months ago - Business Wire

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

10 months ago - Business Wire

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immuno...

10 months ago - Business Wire